

Criteria-Based Consultation Prescribing Program

CRITERIA FOR DRUG COVERAGE

Aclidinium-Formoterol (Duaklir Pressair)

Notes:

- * Intolerance excludes adverse drug reactions that are expected, mild in nature, resolve with continued treatment, and do not require medication discontinuation

Initiation (new start) criteria: Non-formulary **aclidinium bromide-formoterol fumarate (Duaklir Pressair)** will be covered on the prescription drug benefit when the following criteria are met:

- Patient has failed a trial of tiotropium-olodaterol (Stiolto Respimat) **AND** one of the following medications: glycopyrrolate-formoterol (Bevespi Aerosphere), glycopyrrolate-indacaterol (Utibron Neohaler), umeclidinium-vilanterol (Anoro Ellipta); OR patient has an allergy or intolerance* to all of the aforementioned medications.

Criteria for new members entering Kaiser Permanente already taking the medication who have not been reviewed previously: Non-formulary **aclidinium bromide-formoterol fumarate (Duaklir Pressair)** will be covered on the prescription drug benefit when the following criteria are met:

- Patient has failed a trial of tiotropium-olodaterol (Stiolto Respimat) **AND** one of the following medications: glycopyrrolate-formoterol (Bevespi Aerosphere), glycopyrrolate-indacaterol (Utibron Neohaler), umeclidinium-vilanterol (Anoro Ellipta); OR patient has an allergy or intolerance* to all of the aforementioned medications.

Continued use criteria for patients stable on the medication: Non-formulary **aclidinium bromide-formoterol fumarate (Duaklir Pressair)** will continue to be covered on the prescription drug benefit when the following criteria are met:

- Patient has failed a trial of tiotropium-olodaterol (Stiolto Respimat) **AND** one of the following medications: glycopyrrolate-formoterol (Bevespi Aerosphere), glycopyrrolate-indacaterol (Utibron Neohaler), umeclidinium-vilanterol (Anoro Ellipta); OR patient has an allergy or intolerance* to all of the aforementioned medications.